Imaging mass spectrometry differentiates the effects of doxorubicin formulations on non-targeted tissues.
Debeljak Ž, Vinković Vrček I, Drinković N, Micek V, Galić E, Gorup D, Ćurlin M, Mandić D, Bandjak A, Pem B, Kalčec N, Ilić K, Pavičić I, Mimica S, Günday-Türeli N, Türeli E.
Debeljak Ž, et al. Among authors: gunday tureli n.
Analyst. 2022 Jul 12;147(14):3201-3208. doi: 10.1039/d2an00355d.
Analyst. 2022.
PMID: 35699493